Endo En Route To NYSE With Common Stock Exchange Expected Later In 2024
Also, Endo Launched Generic Rival To Delayed-Release Thiola
Endo continues to stride its financial revival path, with the latest plans to list common stock on the NYSE. Also, the firm has just launched a generic tiopronin rival to Travere Therapeutics' Thiola.
